Literature DB >> 12893766

Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays.

Dorothy J Park1, Peter T Vuong, Sven de Vos, Dan Douer, H Phillip Koeffler.   

Abstract

Acute promyelocytic leukemia (APL) is associated with chromosomal translocations involving retinoic acid receptor alpha (RAR alpha) and its fusion partners including promyelocytic leukemia (PML) and promyelocytic leukemia zinc finger (PLZF). Using oligonucleotide arrays, we examined changes in global gene expression mediated by the ectopic expression of either PML/RAR alpha (retinoid-sensitive) or PLZF/RAR alpha (retinoid-resistant) in U937 cells. Of more than 5000 genes analyzed, 16 genes were commonly up-regulated, and 57 genes were down-regulated by both fusion proteins suggesting their role in the APL phenotype. In our APL model, for example, TNFAIP2, TNFR2, ELF4, RAR gamma, and HoxA1 were down-regulated by both fusion proteins in the absence of retinoic acid (RA). RA strongly up-regulated these genes in PML/RAR alpha, but not in PLZF/RAR alpha expressing U937 cells. Expression studies in NB4, retinoid-resistant NB4-R2, normal human CD34+ cells, and APL patient samples strongly suggest their role in the regulation of granulocytic differentiation. Furthermore, combined treatment with tumor necrosis factor alpha (TNF alpha) and RA synergistically enhanced granulocytic differentiation in NB4 cells but not in NB4-R2 cells. Our data indicate that APL pathogenesis and retinoid-induced granulocytic differentiation of APL cells involve genes in the cell death pathway, and that cooperation between the RA and TNFalpha signaling pathways exists. Targeting both the retinoid-dependent differentiation and the cell death pathways may improve leukemic therapy, especially in retinoid-resistant acute myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893766     DOI: 10.1182/blood-2003-02-0412

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  A functional variant at the miR-184 binding site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck.

Authors:  Zhensheng Liu; Sheng Wei; Hongxia Ma; Mei Zhao; Jeffrey N Myers; Randal S Weber; Erich M Sturgis; Qingyi Wei
Journal:  Carcinogenesis       Date:  2011-09-20       Impact factor: 4.944

2.  Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARalpha.

Authors:  Matthew J Walter; John S Park; Rhonda E Ries; Steven K M Lau; Michael McLellan; Sara Jaeger; Richard K Wilson; Elaine R Mardis; Timothy J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-19       Impact factor: 11.205

3.  Reproducibility, fidelity, and discriminant validity of mRNA amplification for microarray analysis from primary hematopoietic cells.

Authors:  Liang Li; Joe Roden; Bruce E Shapiro; Barbara J Wold; Smita Bhatia; Stephen J Forman; Ravi Bhatia
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

4.  Complete characterization of the microRNAome in a patient with acute myeloid leukemia.

Authors:  Giridharan Ramsingh; Daniel C Koboldt; Maria Trissal; Katherine B Chiappinelli; Todd Wylie; Sunita Koul; Li-Wei Chang; Rakesh Nagarajan; Todd A Fehniger; Paul Goodfellow; Vincent Magrini; Richard K Wilson; Li Ding; Timothy J Ley; Elaine R Mardis; Daniel C Link
Journal:  Blood       Date:  2010-09-28       Impact factor: 22.113

5.  Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip.

Authors:  Claudia Hoemme; Abdul Peerzada; Gerhard Behre; Yipeng Wang; Michael McClelland; Kay Nieselt; Matthias Zschunke; Christine Disselhoff; Shuchi Agrawal; Fabienne Isken; Nicola Tidow; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

6.  PML-retinoic acid receptor alpha inhibits PML IV enhancement of PU.1-induced C/EBPepsilon expression in myeloid differentiation.

Authors:  Hitoshi Yoshida; Hitoshi Ichikawa; Yusuke Tagata; Takuo Katsumoto; Kazunori Ohnishi; Yukihiro Akao; Tomoki Naoe; Pier Paolo Pandolfi; Issay Kitabayashi
Journal:  Mol Cell Biol       Date:  2007-06-11       Impact factor: 4.272

Review 7.  Differentiation therapy of leukemia: 3 decades of development.

Authors:  Daniel Nowak; Daphne Stewart; H Phillip Koeffler
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

8.  The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2.

Authors:  Yan Liu; Cyrus V Hedvat; Shifeng Mao; Xin-Hua Zhu; Jinjuan Yao; Hoang Nguyen; Andrew Koff; Stephen D Nimer
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

9.  Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures.

Authors:  Matthew J Walter; John S Park; Steven K M Lau; Xia Li; Andrew A Lane; Rakesh Nagarajan; William D Shannon; Timothy J Ley
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

Review 10.  The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells.

Authors:  Mathias Gehrmann; Jürgen Radons; Michael Molls; Gabriele Multhoff
Journal:  Cell Stress Chaperones       Date:  2008-02-05       Impact factor: 3.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.